Apricus Biosciences, Inc. (NASDAQ:APRI) moved down -18.07% and closed its last trading session at $0.27. This Medical Sector stock currently has the Market Capitalization of 24.65 Million. The Average Volume for the stock is measured as 752.38 Million. The Stock has a 52-Week High of $1.55 and 52-Week Low of $0.26 following the dates, it touched its 52-Week High on Jan 19, 2016 and 52-Week Low on Oct 21, 2016. Currently, the Return on Assets value for the trailing twelve months is -155.5% with the Return on Equity and Return on Investment of 154.8% and 4270% respectively. This firm currently has YTD (year to date) performance of -72.88 Percent which is not good. The Short Ratio for the stock is 3.08.
Apricus Biosciences, Inc. (NASDAQ:APRI) Price to Earnings (P/E) ratio is 0. EPS or Earning per Share stands at $-0.25. The TTM operating margin is 0 percent.
Apricus Biosciences, Inc. (NASDAQ:APRI) is due to report its Earnings on Thu 3 Nov (In 11 Days). The estimated EPS for the current quarter is said to be $-0.07. Following Earnings result, share price were DOWN 19 times out of last 26 Qtrs. The stock has reduced about -25% since it reported its last earnings. The Closing price of Apricus Biosciences, Inc. (NASDAQ:APRI) at Last Earnings was $0.36 as compared to the previous closing price of $0.33. The Predicted Move on the 7th day after Apricus Biosciences, Inc. (NASDAQ:APRI) will release its earnings at about 9%.
By Looking at Earnings History, Out of 12 Quarters when the Earnings were reported, Apricus Biosciences, Inc. (NASDAQ:APRI) beats earnings by 66%, The Stock Missed Earnings 2 times and has met earnings 2 times.
We will discuss the past Quarters Earnings below:
Apricus Biosciences, Inc. (NASDAQ:APRI) reported its previous quarter on 08/04/2016 where it reported the Actual Earnings of $-0.05. The Closing price before the company posted its earnings was $0.36. The Stock declined on the very next day of earnings and maintained its stock price at $0.31 by showing a % change of -13.89 percent from its previous closing price. The Next Day Volume after Earnings was reported as 1.58 Million. On the 7th day After Earnings Report, the stock hit its share price as $0.3 by showing -16.67% decrease from the Stock price Before Earnings were reported.
On 05/09/2016, the stock reported the EPS of $-0.05 where Analysts were projecting the EPS to be $-0.09 showing a difference of $0.04. Thus Surprise Factor was there with 44.4 percent. Before Earnings Announcement on 05/09/2016, the firm had its stock price of $0.46. And immediately on the next day after earnings announcement, the stock inclined 4.35% and closed its trading session at $0.48. On 7th Day after earnings release, Apricus Biosciences, Inc. (NASDAQ:APRI) dropped to -10.87% from $0.46 to $0.41.
On 03/09/2016, Analysts were suspecting EPS of $-0.11/share where Apricus Biosciences, Inc. (NASDAQ:APRI) reported its Actual EPS of $-0.05. Thus showing a Surprise of 54.5 percent. The Closing Price of the stock before earnings was $1.04 while on the Next day the stock closed its trading session at $1.06 with a percentage change of 1.92% from the price of 1.04 before Earnings. The Stock Closing Price on the 7th day of earnings was $1.15.
Apricus Biosciences, Inc., a biopharmaceutical company, focuses on the development and commercialization of products and product candidates in the areas of urology and rheumatology. Its lead product is Vitaros, a topically-applied cream formulation of alprostadil used for the treatment of erectile dysfunction. The companys marketing partners for Vitaros include Laboratoires Majorelle, Bracco S.p.A., Hexal AG (Sandoz), Takeda Pharmaceuticals International GmbH, Recordati Ireland Ltd. (Recordati S.p.A.), Ferring International Center S.A. (Ferring Pharmaceuticals), Mylan NV, Neopharm Scientific Limited, Elis Pharmaceuticals Limited, and Global Harvest Pharmaceutical Corporation. It also develops second-generation Vitaros, a proprietary stabilized dosage formulation that is expected to be stored at room temperature conditions; and Fispemifene, a tissue-specific selective estrogen receptor modulator that is in Phase IIb clinical trial to treat secondary hypogonadism, lower urinary tract symptoms, and chronic prostatitis in men. In addition, the company plans to initiate a Phase IIb trial for RayVa to treat Raynauds phenomenon associated with scleroderma; and develops Femprox, a product candidate for the treatment of female sexual interest/arousal disorder. It operates in Latin America, Europe, and internationally. The company was formerly known as NexMed, Inc. and changed its name to Apricus Biosciences, Inc. in September 2010. Apricus Biosciences, Inc. was founded in 1987 and is headquartered in San Diego, California.